Okenrav
Posted - 18 hours ago
$VKTX $RHHBY data 👇. No word of sample size, drop-out rate, side effects. https://www.roche.com/media/releases/med-cor-2024-05-16
NYC_SUPAPUMPA_9B
Posted - 20 hours ago
$VKTX $TERN $ALT $RHHBY Anyone could verify that Roche had 14 cohorts & all they released is one(best) most likely maxed out because of tolerance issue? I came across this statement over x.com I am not a MD or health science expert so what I understood from Roche PR is the opposite to this statement, that the data were for all cohorts except one to be published later.
BuyHighSellLowGER
Posted - 2 days ago
$RHHBY How much will their CT-388 affect sales of Ozempic soon? Is it time to secure profits? $NVO
DonCorleone77
Posted - 2 days ago
$VKTX $RHHBY Viking weakness on Roche obesity data 'overdone,' says BTIG BTIG notes that Viking Therapeutics (VKTX) shares are trading down about 11% today following Roche's (RHHBY) initial efficacy data from the Phase Ib study of dual GLP-1/GIP agonist CT-388, but the firm views the weakness in Viking shares being "overdone." The disclosure did not present safety/tolerability data from the study, which is an important consideration for the class, or the dose titration used and which dose cohort was being presented, notes the analyst, who adds that "Roche's data disclosure today does not take away from our conviction on Viking shares." The firm, which continues to view Viking's VK2735 in both subcutaneous and oral formulations as "being positioned well competitively in the hot obesity market," has a Buy rating and $125 price target on Viking shares.
Quantumup
Posted - 2 days ago
BTIG views weakness in $VKTX (Buy/$125) as being overdone: $RHHBY disclosure did not present safety/tolerability data from the study, which is an important consideration for the class, or the dose titration used and which dose cohort was being presented; $RHHBY "data disclosure today does not take away from our conviction on Viking shares." BTIG continues to view Viking's VK2735 in both subcutaneous and oral formulations as being positioned well competitively in the hot obesity market.
Quantumup
Posted - 2 days ago
Raymond James upgraded $VKTX 💪🏽Buy/$116 was Outperform/$115 ~Bull Case=$150 $RHHBY released a few datapoints for its sub-cu wkly GLP-1/GIP asset CT-388, which RJ views as the closest comp for $VKTX $RHHBY has made it as difficult as possible to compare CT-388 to VK2735 RJ models about 19.8% unadjusted weight loss at week 24 for VK2735 if treated w/ a flat 15mg dose from week 13 onward/contends that VK2735 appears to be holding up against the biggest competitive overhang following the data reported by $RHHBY :
ZManicItalian
Posted - 2 days ago
$RHHBY I'm in! Nice dividend 👍
Also holding VKTX and LLY.
Theflash88
Posted - 2 days ago
$RHHBY Good for a long term hold.. nice dividend.
Only Phase 1 GLP-1
DonCorleone77
Posted - 2 days ago
$VKTX $RHHBY Viking upgraded to Strong Buy at Raymond James after 'opaque' competitor update As previously reported, Raymond James analyst Steven Seedhouse upgraded Viking Therapeutics (VKTX) to Strong Buy from Outperform with a price target of $116, up from $115. Roche (RHHBY) released "a few datapoints" for its subcutaneous weekly GLP-1/GIP asset CT-388, which the firm views as the "closest competition" for Viking, and Roche "has made it as difficult as possible" to compare CT-388 to VK2735, the analyst tells investors. The firm models about 19.8% unadjusted weight loss at week 24 for VK2735 if treated with a flat 15mg dose from week 13 onward, notes the analyst, who contends that VK2735 "appears to be holding up against the biggest competitive overhang" following the data reported by Roche.
DonCorleone77
Posted - 2 days ago
$VKTX $RHHBY $LLY Roche data falls short of Viking weight loss drug, says Truist Truist analyst Joon Lee keeps a Buy rating on Viking Therapeutics (VKTX) with a $120 price target after Roche (RHHBY) disclosed that its CT-388 dual agonist drove mean placebo-adjusted weight loss of 18.8% over 24 weeks. The data is impressive but falls short of efficacy Viking's VK2735 reported in the Phase 2 VENTURE, the analyst tells investors in a research note. The firm says that caveats of cross-trial comparisons notwithstanding, the slope of weight loss with VK2735 looks steeper and likely to exceed weight loss reported by CT-388 at later time points. However, both appear to be significantly better than tirzeptatide, the current market leader from Eli Lilly (LLY), adds Truist. It continues to view VK2735 as the better drug and possibly best-in-class.
Alligator
Posted - 2 days ago
$VKTX I read this… Is the side effect for $RHHBY Carmot (50% nausea , 33% vomiting) true ? and shouldn’t it be a deal breaker for them?
Perhaps the strategy is all of that vomiting causes a person to lose weight?
Phil7777777777
Posted - 2 days ago
$VKTX $NVO $AMGN $RHHBY
Power2k
Posted - 2 days ago
$VKTX First $NVO, then $AMGN, and now $RHHBY, every time a big name releases early obesity trial data (even incomplete or questionable), we got hammered. Nevertheless, VK2735 is still the best-in-class GLP/GIP dual agonist. Ain't selling, and Holding thru BO or final approval.
RainbowTrump
Posted - 3 days ago
$VKTX the vomit rate for $RHHBY Carmot looks absolutely nuts. 50% nausea , 33% vomiting. Could save money and just shove your fingers down your throat. Skip the injection
LMDXWILLBOOM
Posted - 3 days ago
$RHHBY Not yet my friend. $lmdx will take this to 60.00 & beyond when our shares convert to rhhby including shares sold short. Believe it!
LMDXWILLBOOM
Posted - 4 days ago
$LMDX $RHHBY Can thank us later when they do the conversion causing shares sold short to convert as well. Rhhby may run to 60 or 70 🚀🚀🚀
DonCorleone77
Posted - 5 days ago
$NVO $RHHBY $GMAB Novo Nordisk mim8 data near Jefferies' 'best' case scenario Jefferies says positive headline Phase 3 data for Novo Nordisk's (NVO) mim8 in haemophilia A "may near our 'best' case scenario," with convenient once-monthly dosing seeming similarly effective to once-weekly and efficacy data that may challenge Roche's (RHHBY) incumbent Hemlibra. Based on the press release, the firm "could justify modest" Novo stock upside, Genmab (GMAB) shares being up 2%-4% and Roche shares being down 2%-3%, the analyst tells investors. Jefferies has an Underperform rating on Novo shares and Hold ratings on both Genmab and Roche.
Diefreeandsell
Posted - 1 week ago
@johnnybokc got approved for multiple sclerosis drug Briumvi in Dec 2022 and slowly taking mkt share from ocrevus $RHHBY and kesimpta $NVS .
Nosferatus
Posted - 1 week ago
$MCRB $XBI $NVS $RHHBY $SPX please watch this video from minute 15. we will soon be bought at a minimum of USD 10 per share https://youtu.be/94NcNu12hDE?si=yAmH6VNYX6XFQ18E
Grande4587258
Posted - 1 week ago
$RHHBY Blast 💥 Off
LMDXWILLBOOM
Posted - 1 week ago
$LMDX The structure of this deal is very collaborative sounding. What shareholders receive i cannot say for sure, but since FDA belongs to Lumiradx according to FDA themselves that can only mean I was correct in my assumption that Columbia holds the device they are marketing. It could also mean that we'll also receive shares of $RHHBY in a 9 or 10:1 ratio since Roche has a pending amount set aside & who knows with DNEDX. Patience friends it's coming.
DeepDown
Posted - 1 week ago
$OMGA worth to buy some. $RHHBY and $NVO will pay up
LMDXWILLBOOM
Posted - 2 weeks ago
$LMDX don't worry guys! I'm trolling both $rhhby & Lumira on linked in.
Thagger
Posted - 2 weeks ago
@FalconTech Sub q seems is a non starter. Just PR from $RHHBY. A lot of things can happen during the infusion and I’m not sure sub q will be any less. When your heart rate goes up to 180+ what do you do? Your throat itches and you have hives and whatever else side effects who will give you Benadryl, solumerol, steroids etc when you’re already freaking out? Most people I would think would opt for infusion center.
InvestingBlue
Posted - 2 weeks ago
$SPY starting a position in $FMC and $RHHBY both stocks are a great value currently.
InvestingBlue
Posted - 2 weeks ago
$RHHBY why does this perform so poorly? Company is a super value.
_rand0m
Posted - 2 weeks ago
$TGTX $RHHBY look out, Briumvi is coming.
$NVS look out, sub-cutaneous Briumvi is coming.
LilJimmy007
Posted - 2 weeks ago
$TGTX does $RHHBY CEO see it yet?